Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
33 patients, while 36 patients had a previous gastrectomy.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Contrastingly, PPI use was not an independent predictor of OS. [CONCLUSION] PPIs may reduce the efficacy of nivolumab, and their use should be carefully considered in patients receiving nivolumab.
[BACKGROUND] Proton pump inhibitors (PPI) have been shown to decrease the efficacy of immune checkpoint inhibitors in patients with various cancer types.
APA
Shibano M, Takahashi M, et al. (2025). Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.. Immunotherapy, 17(5), 331-338. https://doi.org/10.1080/1750743X.2025.2491300
MLA
Shibano M, et al.. "Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.." Immunotherapy, vol. 17, no. 5, 2025, pp. 331-338.
PMID
40228034 ↗
Abstract 한글 요약
[BACKGROUND] Proton pump inhibitors (PPI) have been shown to decrease the efficacy of immune checkpoint inhibitors in patients with various cancer types. However, there are few reports on their effect on patients with gastric cancer (GC). Therefore, we investigated the efficacy of nivolumab in patients with GC receiving PPI.
[METHODS] This retrospective study analyzed data of patients who received nivolumab monotherapy for unresectable advanced or recurrent GC at Osaka Metropolitan University Hospital between September 2017 and December 2021. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. PPI use was defined as within 30 days before and after initiation of nivolumab monotherapy.
[RESULTS] Seventy-seven eligible patients were included in this analysis. PPIs were used in 33 patients, while 36 patients had a previous gastrectomy. Multivariate analysis revealed that only PPI use was an independent predictor of PFS (hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.03-3.64, = 0.042). Contrastingly, PPI use was not an independent predictor of OS.
[CONCLUSION] PPIs may reduce the efficacy of nivolumab, and their use should be carefully considered in patients receiving nivolumab.
[METHODS] This retrospective study analyzed data of patients who received nivolumab monotherapy for unresectable advanced or recurrent GC at Osaka Metropolitan University Hospital between September 2017 and December 2021. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. PPI use was defined as within 30 days before and after initiation of nivolumab monotherapy.
[RESULTS] Seventy-seven eligible patients were included in this analysis. PPIs were used in 33 patients, while 36 patients had a previous gastrectomy. Multivariate analysis revealed that only PPI use was an independent predictor of PFS (hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.03-3.64, = 0.042). Contrastingly, PPI use was not an independent predictor of OS.
[CONCLUSION] PPIs may reduce the efficacy of nivolumab, and their use should be carefully considered in patients receiving nivolumab.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Nivolumab
- Male
- Stomach Neoplasms
- Female
- Proton Pump Inhibitors
- Aged
- Retrospective Studies
- Middle Aged
- Immune Checkpoint Inhibitors
- Treatment Outcome
- 80 and over
- Neoplasm Recurrence
- Local
- Adult
- Progression-Free Survival
- Antineoplastic Agents
- Immunological
- Proton pump inhibitors
- gastric cancer
- microbiome
- nivolumab
- previous gastrectomy
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.